GlassScriptPhysician profile
Anthony A Meluch
NPI 1679521090
$80,409.58
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $3,455 · 2021: $7,693 · 2022: $9,372 · 2023: $2,065 · 2024: $49.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $742.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $73,195.17 | 2019-2023 | Cabometyx |
| Genzyme Corporation | $2,113.27 | 2019-2023 | |
| Aveo Pharmaceuticals, INC. | $1,148.46 | 2022-2023 | Fotivda |
| Merck Sharp & Dohme LLC | $469.34 | 2019-2023 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $320.52 | 2019-2023 | Lynparza, Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $291.22 | 2019-2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $249.10 | 2019-2023 | |
| Janssen Biotech, INC. | $228.94 | 2019-2023 | Imbruvica, Darzalex |
| Amgen INC. | $222.98 | 2019-2023 | Kyprolis, Blincyto |
| Genentech USA, INC. | $199.58 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $125.47 | 2019-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $113.69 | 2019-2023 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $111.43 | 2019-2023 | |
| Astellas Pharma US INC | $102.43 | 2019-2024 | Xtandi |
| Gilead Sciences, INC. | $95.59 | 2019-2023 | Trodelvy |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Meluch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.